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Abstract
Background: T-cells are endowed with a functional cell-based renin angiotensin system (RAS), related with and
independent by circulating RAS that can autonomously synthesize angiotensin (Ang) II. Angiotensing converting
enzyme (ACE) is the key step for the regulation of the synthesis of Ang II by RAS and T-cell ACE gene expression
was reported to be up-regulated in hypertensives with low grade inflammation. Ang II and T-cells play a major role in
the systemic inflammation that occurs in unstable angina patients, but whether T-cell based RAS is directly involved
is unknown.
This study was aimed at measuring ACE gene expression and enzymatic activity in the cell pellet and in the
supernatant of human cultured circulating T-cells obtained from control subjects, hypertensive or unstable angina
patients. C reactive protein (CRP) levels as a marker of systemic inflammation were also investigated.
Methods: mRNA for ACE gene expression was obtained in T cells isolated from peripheral blood and quantified
by real time transcriptase–polymerase chain reaction (PCR); mRNAs for INF-gamma was semi-quantified versus the
housekeeping gene glyceraldeyde-3-phosphate dehydrogenase (GAPDH) by reverse transcriptase (RT) PCR. ACE
activity in cell pellet and in the culture medium (supernatant) was measured by the high performance liquid
chromatography (HPLC) assay of a synthetic substrate. Plasma renin activity (PRA) and Ang II levels were
measured by radioimmunoassay and high sensitive C Reactive Protein (hsCRP) by a commercial kit.
Results: In hypertensive and more markedly in anginal patients increased mRNA levels for ACE, augmented
cell-based ACE enzymatic activity and Ang II levels were measured in cultured circulating T-cells when compared
with data obtained in T cells from controls (p<0.05 for alls). The addition of Ang II to the T-cell pellet further increase
ACE activity and Ang II synthesis. In anginal patients who showed the highest ACE gene expression and enzymatic
activity and hsCRP values, Ang II stimulation of T-cells induced an almost complete release of ACE in the
supernatant.
Conclusions: In anginal patients with hsCRP levels >3 mg/dl a marked up-regulation of circulating T-cell-based
ACE gene expression and activity did occur in T-cell culture, further amplified by Ang II. According to our in vitro
findings, in vivo activated T-cells could autonomously increase local de novo Ang II synthesis in tissues where they
migrate and play a role in coronary plaque rupture and microvessel damage of unstable angina.
Keywords: Angiotensin-converting enzyme; Angiotensin II; T-cell;
Unstable angina; Hypertension
Introduction
Growing evidence supported a tight relationship between Ang II
and inflammation, because Ang II up-regulates the inflammatory
response and inflammatory T-cells are fully equipped with RAS
components and deliver new synthesized Ang II to sites of
inflammation, independently of the activation of systemic and tissue-
based RAS [1-3]. Human circulating T-cells but not B-cells are
endowed with autonomous cell-based RAS [4].
Ang II participates in the recruitment of T-cells via the direct
activation of inflammatory cells or via the up-regulation of the
synthesis of adhesion molecules and/or chemokines by resident cells
[2,3].
The ACE gene expression and enzymatic activity have a key-role in
the increase and decrease in Ang II synthesis associated to systemic,
local or cell-based RAS activation or inhibition [5]. An increased
expression of ACE gene and activity was reported in circulating T-cells
in hypertensive patients with low grade inflammation [6]; augmented
levels of tissue ACE strictly related to the amount of infiltrated
inflammatory T-cells were shown in coronary plaques and
microvessels of left ventricular tissues of unstable angina patients [7,8],
but the direct involvement of T-cells based RAS in unstable angina is
still a matter of debate. In acute coronary syndromes (ACS) an
imbalance of T-cell homeostasis does occur and a higher systemic
frequency of activated T-cells compared with those with stable angina
was reported; T-cell repertoire perturbation plays a pivotal role in
coronary instability [9-12]; however, at the best of our knowledge
whether and how an up-regulation of circulating T-cell based ACE
gene expression and activity could participate to ACS inflammation
was not studied.
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The present study was aimed at investigating the pattern of T-cell
based ACE gene expression and enzymatic activity (assayed in pellet
and in supernatant) in cultured circulating T-cells obtained by ACS
patients with high (>3 mg/dl) sensible protein C reactive (hsCRP)
values. The same data were also obtained in T-cell from control
subjects with normal hsCRP values and from hypertensives with low
grade inflammation (hsCRP>2 mg/dl).
Methods
Subjects investigated
T-lymphocytes were obtained from 11 (6 males, 5 females, 57-69
years) patients with unstable angina (UA) in class IIIB of Braunwald’s
classification admitted to our Coronary Care Unit and from 15 (9
males, 6 females, 45-67 years) subjects with World Health
Organization stage II essential hypertension who attended to our out-
patients’ clinic. Ten (6 males, 4 females, 39-56 years) normotensive
subjects were enrolled in the study as control group comparable for age
and sex to anginal patients and hypertensive group.
Diagnosis of UA patients was performed according to the 2015
European Society of Cardiology Guidelines for the management of
ACS in patients presenting without persistent ST elevation [13].
Only patients with recent onset (7 days before admission) of angina
who had at least 2 episodes of angina at rest or 1 episode lasting more
than 20 minutes during the preceding 24 hours associated with
transient ischemic ST-segment changes and high sensitivity troponin T
levels <0.1 ng/mL (troponin T–negative) were included in the study.
UA patients received nitrates.
Exclusion criteria were secondary forms of arterial hypertension,
ischemic heart disease/acute coronary syndrome (only for
hypertensive and controls) or stroke in the previous 6 months,
impaired glucose tolerance or diabetes mellitus, renal failure
(creatinine clearance <60 ml/min), presence of a major illness such as
cancer, liver disease, chronic and acute inflammatory disease or
infectious disease in the previous 3 months. No subject was on
treatment with ACE-inhibitors, AT1 receptor antagonists, diuretics,
statin or anti-inflammatory drugs. Main demographic and clinical








Males/Females 6/4 6/5 9/6
Age (years) 46 ± 9 63 ± 6 56 ± 11 p<0.01
Smokers (%) 2 (20) 8 (67) 10 (66) p<0.01
Hypertension (%) 0 7 (46) 15 (100) p<0.01
Fasting glucose (mg/dl) 84 ± 9 89 ± 10 96 ± 5 ns
Total cholesterol (mg/dl) 188 ± 24 191 ± 45 193 ± 40 ns
HDL- cholesterol (mg/dl) 52 ± 11 54 ± 16 46 ± 17 ns
Creatinine (mg/dl) 0.79 ± 0.09 0.89 ± 0.15 0.89 ± 0.27 ns
LVM (g/m2) 106.3 ± 17.3 106.5 ± 18.0 107.0 ± 22.4 ns
LVEF (%) 60.4 ± 5.2 54.9 ± 5.1 53.6 ± 4.5 ns
LVM: Left Ventricular Mass; LVEF: Left Ventricular Ejection Fraction
Table 1: Clinical characteristics of controls, unstable angina and hypertensive patients.
According to hsCRP values at enrollment, only hypertensive
patients with low grade inflammation (hsCRP>2 mg/l) had been
included; assay of hsCRP levels and other general chemical tests were
done as a part of a routine medical check-up.
The protocol of this study complies with the principles of the
Helsinki declaration and was approved by the Ethical Committee of
our Institution. All patients gave their written informed consent to
participate and to have their data analyzed for the study.
Experimental procedures
T-lymphocyte isolation: Fifty milliliters of peripheral venous blood
were drawn from the antecubital vein, collected in a sterile flask
containing 3.8% sodium citrate (9/1, vol/vol) and T-lymphocytes
isolation was carried out according to our previous report [4,6] (Figure
1). Magnetic beads conjugated with antihuman CD 3 (Miltenyi Biotec,
GmbH, Bergisch Gladbach, Germany) were used for positive selection
of T-lymphocytes. In each incubation experiment, mRNA expression
of ACE, INF-γ and ACE activity and Ang II concentrations were
studied in cell pellet. ACE activity was also investigated in the
supernatants, since ACE can be shed by T-cells [6]. To study the effect
of stimulation by Ang II on ACE expression and activity and Ang II
concentrations, T-lymphocytes were cultured in humidified
atmosphere with 5% for 6 or 18 or 24 h with and without 0.1 pmol/l
Ang II addition to the culture medium.
Real-Time PCR for the assay of ACE gene expression and RT-
PCR analysis for the assay of INF-gamma gene expression in
T-cells from controls, hypertensive and anginal patients
Isolation of total RNA and real time PCR for ACE gene expression
was performed as detailed in our previous paper [6]. Relative ACE
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gene expression was calculated as 2-∆Ct (∆Ct = Ct of the target gene
minus Ct of beta-actin). mRNAs for INF-gamma were semi-quantified
versus the housekeeping gene GAPDH by RT-PCR (Applied
Biosystems) using specific primers.
Figure 1: The flow chart illustrates total population studied divided
in 3 cohorts with parameters investigated in each of them.
Assay of ACE activity in the T-cell pellet and in the
supernatant of cultured T-cells from controls, hypertensive
and anginal patients
T-cell ACE activity was measured by the quantification of hyppuric
acid (HA), produced during the enzymatic reaction of ACE on a
synthetic substrate hyppuril-hystidyl-leucine (HHL) and assayed by
HPLC analysis using a spectrophotometric detector at 228 nm
absorbance [6].
Measurement of plasma renin activity (PRA), Ang II and
hsCRP
PRA measurement was performed with a commercial kit (Sorin
Biomedica). Ang II levels were determined by radioimmunoassay after
C18 Sep-Pak cartridge extraction and HPLC separation [6]. hsCRP
was measured by a commercial kit (Beckman, Brea, CA) with the
lowest detection point of 0.1 mg/dl [6].
Statistical analysis
Data have been stored in a dedicated data-base and analyzed by
IBM-SPSS 20 for Windows® statistical software (IBM-SPSS Inc., USA).
Variables were reported as mean ± SD. Within-groups comparisons
(data at baseline vs. 24 h; baseline vs. 24 h plus Ang II and 24 h vs. 24 h
plus angiotensin II) were made by paired Student t-test analysis. In
order to analyze differences in ACE gene expression and enzymatic
activity throughout the time-course among the three groups, an
analysis of variance (ANOVA) for repeated measures was used.
Statistical significance was taken as p<0.05 for all calculations.
Results
ACE gene expression and ACE activity without Ang II
stimulation in T-cells from control subjects, ACS and
hypertensive patients
Figure 2 shows the pattern of ACE gene expression in T-cells
cultured without Ang II stimulation in controls and in patients: in
control subjects T-cell ACE gene expression was detectable at baseline
and did not significantly change at 18 and 24 hours of cell-incubation.
T-cells from ACS patients showed significantly higher (p<0.001) ACE
mRNA levels than those expressed by T-cells from controls at baseline
and throughout cell-incubation. Hypertensive patients had higher
(p<0.01) T-cells ACE mRNA levels than those observed in T-cells from
controls, but lower (p<0.01) than those by T-cells from ACS patients.
No changes in ACE gene expression were observed during the
incubation time.
Figure 2: T-lymphocytes ACE gene expression without and with
Ang II–stimulation in controls, anginal and hypertensive patients.
Table 2 shows the different pattern of ACE activity assayed in the
pellet and in the supernatant of T-cells cultured without Ang II
stimulation: in cultured T-cell from control subjects, ACE activity was
detectable in the pellet at baseline and at 24 hours. In the supernatant
T-cell ACE activity from controls was no detectable at baseline and was
very low at 24 hours of incubation. In anginal patients T-cell ACE
activity was significantly higher (p<0.001) than that assayed in controls
both in the pellet and in the supernatant; specifically, at 24 hours T-cell
ACE activity did not change in the pellet, but significantly increased in
the supernatant (p<0.001 vs controls). In hypertensive patients T-cell
ACE activity in the pellet and in the supernatant was significantly
(p<0.001) higher than those assayed in controls at baseline and at 24
hours and not significantly different when compared with ACS levels;
in the supernatant ACE activity was significantly (p<0.001) lower than
those observed in ACS patients at 24 hours (Table 2).
ACE gene expression and ACE activity in cultured T-cell
from control subjects, anginal and hypertensive patients after
Ang II stimulation
In control subjects the addition of 0.1 pmol/l Ang II to the T-cell
culture medium caused a significant (p<0.01 vs no Ang II stimulus)
increase in T-cell ACE mRNA level at the 24 hours of incubation
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(Figure 2). In T-cells from controls Ang II stimulus caused a significant
increase (p<0.05) in T-cell pellet ACE activity at 24 hour and was
associated with the spontaneous release of about the 20% of total T-cell
ACE activity into the supernatant (Table 2).
ACE activity
(μU/106 cells)
Baseline 24 hrs 24 hrs + Ang II
Control subjects
Pellet 6.1 ± 2.1 6.5 ± 1.9 9.9 ± 1.6*
Supernatant n.d. 0.6 ± 0.4# 2.2 ± 0.4#
Unstable angina
Pellet 26.7 ± 8.9 28.1 ± 10.2 18.5 ± 3.8*#
Supernatant n.d. 22.7 ± 9.5# 47.1 ± 10.4$
Hypertensives
Pellet 20.30 ± 2.9 19.9 ± 1.65 17.2 ± 1.82
Supernatant n.d. 1.22 ± 0.95 11.73 ± 1.05$
n.d.: non detectable
within each group studied; *24 h + Ang II vs baseline p<0.01; #24 hrs vs. 24 h +
Ang II p<0.01; $24 hrs vs 24 hrs + Ang II p<0.001
at ANOVA unstable angina and hypertensives p<0.001 vs controls for pellet and
supernatant ACE activity; unstable angina vs hypertensives p<0.001 for
supernatant ACE activity
Table 2: ACE activity in pellet and supernatant and Ang II pellet
concentration of T-lymphocytes from controls, unstable angina and
hypertensive patients without or with the addition of 10-13 mol/l Ang II
in cell culture medium.
Also in T-cells from anginal patients the addition of Ang II to the
cell medium significantly (p<0.001) increased T-cell ACE mRNA
levels; the rate of increase was higher than that observed in T-cell from
control subjects and the highest peak value for ACE gene expression
was reached at 18 hours. In T-cell from hypertensive patients the Ang
II stimulus caused a significant (p<0.01 vs no Ang II addition) early
(peak at 6 hours) increase in T-cell ACE gene expression that was
respectively significantly higher (p<0.001) and lower (p<0.001) than
that shown by T-cells from controls and from anginal patients
respectively (Figure 2).
In T-cells from anginal and hypertensive patients the addition of
Ang II to the cell medium was not associated with an increase in the
ACE activity of the T-cell pellet, but with a significant increase in the
ACE activity in the supernatant that reached about the 64% of the
pellet ACE activity in cultured T-cells from hypertensives and about
the 260% in cultured T-cells from ACS patients.
Effect of Ang II–stimulation on T-cell INF-gamma gene
expression
In controls and in patients, T-cell INF-gamma gene expression was
detectable under baseline condition and did not significantly change at
18 and 24 hours of cell- Conversely, the addition of Ang II to the T-cell
culture was associated with a significant increase in T-cell INF-gamma
mRNA levels, that peaked at the 24th hour without differences between
values observed in T-cells from controls, anginal and hypertensive
patients (data not shown).
Ang II concentration in the pellet of cultured T-cells from
controls, unstable angina and hypertensive patients
In the T-cell pellet from control subjects Ang II concentration was
176.5+17.9 fmol/mg proteins at baseline and did not significantly
change after 24 hours of incubation; Ang II levels significantly
increased after the addition of Ang II to the culture medium (Table 3).
In T-cell pellet from anginal patients Ang II concentrations was
significantly higher (p<0.01) than that assayed in controls both without
and with Ang II stimulation (Table 3).
Ang II concentration in T-cell pellet from hypertensives was always
significantly (p<0.01) higher than those assayed in controls (Table 3)
and differed from ACS Ang II concentrations at baseline and at 24
hours with Ang II stimulation.
Ang II (fmol/mg
proteins)
Baseline 24 hrs 24 hrs + Ang II
Control subjects
24 hrs vs baseline 176.5 ± 17.9 180.2 ± 13.4*# 257.2 ± 18.1*
p=0.520
Unstable angina
24 hrs vs baseline 408.0 ± 37.2 373.1 ± 39.6# 476.4 ± 30.7*
p=0.570
Hypertensives
24 hrs vs baseline 274.9 ± 31.2 321.6 ± 34.8 378.9 ± 30.7*
p=0.672
within each group studied; *24 h + Ang II vs baseline p<0.01; # 24 h vs. 24 h +
Ang II p<0.01;
at ANOVA unstable angina vs controls p<0.001, hypertensives vs controls
p<0.01; unstable angina vs hypertensives p<0.01.
Table 3: Ang II concentration in pellet of T-lymphocytes from controls,
unstable angina and hypertensive patients without or with the addition
of 10-13 mol/l Ang II in cell culture medium.
Plasma renin activity in controls, angina and hypertensive
patients
In the control subjects, PRA in venous blood was 10.5+1.5 pmol.
L-1.min-1 (range, 4.5 to 15.2 pmol. L-1.min-1). PRA levels in anginal
and hypertensive patients were 10.1+1.2 pmol. L-1.min-1 (range, 4.8 to
14.7 pmol. L-1.min-1) and 11.2+0.9 pmol. L-1.min-1(range, 4.0 to 16.4
pmol. L-1.min-1) respectively, without significant differences between
the three groups studied.
Discussion
Our data show that in patients with unstable angina (ACS)
circulating T-cell based ACE mRNA expression and enzymatic activity
were markedly increased when compared to levels found in T-cell from
controls and hypertensive patients and resulted in a de novo enhanced
cell-based Ang II production. Only in cultured T-cell from anginal
patients ACE activity was detectable not only in the pellet but also in
the supernatant under baseline conditions; remarkably, the addition of
Ang II stimulus to these cultured T-cells caused the almost complete
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release of ACE activity in the medium. This pattern of T-cell ACE
genetic expression and enzymatic activity was peculiar of enrolled ACS
patients with hsCRP >3 mg/dl and was markedly different not only
from that observed in T-cell from controls but also from hypertensives
with low grade inflammation (hsCRP >2 mg/dl). The normal PRA
values found in ACS patients showed that the activation of T-cell RAS
was selective and occurred in the absence of systemic RAS
involvement. According to our data in ACS patients activated T-cell
not only contribute to the acute systemic inflammatory reaction of
unstable angina as cells of adaptive immunity [9,10], but also through
the autonomous up-regulation of T-cell based RAS [5,6]. The increase
in the synthesis of Ang II sustained by activated T-cells could have
clinical relevance when it occurs into coronary plaques or microvessels
where circulating T-cells are known to migrate [14,15]. No systemic
effect can be hypothesized because of the low quote of Ang II
synthesize by T-cells when compared to those produced by tissue-
based or systemic RAS and because of the very short half-life of Ang II
[16,17].
The enhanced de novo Ang II production by T-cells could start a
dangerous positive loop in inflamed tissues and further amplify the
activation of the immune response [18]. Remarkably, our in vitro
findings of the marked release of ACE enzymatic activity in the
supernatant by cultured T-cell from anginal patients, in vivo could
translate in the local activation by de novo T-cell synthesized Ang II of
other cells endowed with AT1-R such as endothelial and monocyte
cells inside coronary plaques or microvessels [19,20]. Data available in
literature reported that under Ang II stimulus AT-1 receptors of T-cells
are upregulated 10 times and that T-cells exposed to Ang II have an
increased ability to secrete TNF-alfa and INF-gamma as also
confirmed in our in vitro experiments. In agreement with our in vitro
findings, in myocardium of unstable angina patients an increased
immunostaining for INF-gamma and TNF-alfa was shown next to
inflammatory cells and was proved to be dumped in patients under
pharmacological ACE inhibition [7,16]. Moreover, T-cells are involved
in the process of endothelial dysfunction that contributes to the plaque
destabilization in unstable angina and several studies have shown that
T-cells infiltrate into atherosclerotic plaques and co-localize with ACE
positivity at immunostaining [21-25]. According to our findings the
instability of a plaque so to be a culprit lesion could be mediated by an
increased de novo local Ang II production by activated circulating T-
cells migrated inside plaques [17,18,26].
Finally, the local increased Ang II production by circulating
cultured T-cells shown in our ACS patients could in vivo induce an
oxidative burst in the endothelium, smooth cells , macrophages and T-
cells of ischemic myocardium. Indeed, experimental studies reported
that Ang II stimulus was shown to induce a marked increase in the
ability of T-cells to produce reactive oxygen species, which in turn
amplify the immune response [27,28].
Limits
Since different T-cell populations are known to operate with
opposite roles on the regulation of the immune system, we are not able
to specify whether T-cell ACE and Ang II upregulation was linked to a
specific T-cell subpopulation. In experimental models, 8 weeks of
exogenous Ang II treatment accelerated the development of
atherosclerosis and prompted a switch from a stable-to-unstable
plaque that was associated with a change in CD4+ T lymphocyte
activity; valsartan inhibited the effect of Ang II and significantly
increased the frequency of Th2 and Treg regulatory cells [29]. In
different atherosclerotic-prone models the proatherogenic properties
of Th1 were shown and evidence from clinical investigations was
collected that the upregulation of Th1 immune response was
overwhelming in patients with ACS [30] and that an Ang II-due
imbalance between Th1 and Th2 response might play a role in plaque
rupture [29,30]. As a whole these findings strongly suggest that the
activation of T-cell RAS found in angina patients could play a role in
the dysregulation in T-cell populations underlying ACS. Dedicated
studies are needed to investigate this issue.
Conclusions
In ACS patients with a systemic inflammatory reaction marked by
high hs-CRP levels, a selective activation of circulating cultured T-cell
based RAS did occur with enhanced ACE gene expression and activity
that resulted in an increased de novo Ang II synthesis. Our in vitro
findings strongly support that in vivo, once migrated into inflamed
tissues, activated T-cells from ACS patients can autonomously increase
the local concentration of ACE and Ang II and amplify the
inflammatory reaction underlying coronary plaque activation and
microvessel damage.
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